ECTRIMS 2018: Updates on Progressive MS
Which subgroups of progressive MS should be treated? Dr. Xavier Montalban, professor at the University of Toronto, presented an overview of treatments in…
ECTRIMS 2018: Risk Factors for multiple sclerosis (MS)
Overview of the growing list of potential risk factors for MS Dr. Ali Manouchehrinia, Assistant Professor at the Karolinska Institutet, presented an overview…
Guten Tag! The research team will be live at the world’s largest conference in Berlin, Germany next week
The MS Society of Canada’s research team is preparing to fly over the Atlantic to the exciting city of Berlin, Germany to attend…
3rd Scientific Congress of the Progressive MS Alliance: Making a difference through rehabilitation and Symptom Management (Part 3)
While researchers are forging ahead with great ideas in symptom management and rehabilitation, we also heard about the complexity of factors that affect…
3rd Scientific Congress of the Progressive MS Alliance: Making a difference through rehabilitation and Symptom Management (Part 2)
Taking the lessons learned from stroke research (part 1) and moving forward to develop new projects and programs is important for the advancement…
3rd Scientific Congress of the Progressive MS Alliance: Making a difference through rehabilitation and Symptom Management (Part 1)
“The whole is greater than the sum of its parts,” quoted by Aristotle and reiterated by Dr. Anthony Feinstein, a neurologist at Sunnybrook…
Incidence and Prevalence: What do they mean, how new numbers are identified and why they are important?
Incidence and prevalence are two terms that are frequently used in epidemiology but are often mixed up or used incorrectly. Epidemiology is a branch of research that…
